Cellect Biotechnology (APOP) Stock Climbs On IP News

Cellect Biotechnology APOP Stock News

Cellect Biotechnology Ltd – ADR (NASDAQ: APOP) is rocketing in the market this morning, trading on more than 130% gains after announcing intellectual property news. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

APOP Stock Climbs After Strengthening It’s IP Portfolio

In a press release issued early this morning, Cellect Biotechnology said that it has received official communication from two jurisdictions with regard to intellectual property. The two jurisdictions included the European Patent Office and the Israeli Intellectual Property Office.

In the release, the company said that the communication surrounded the intention of these jurisdictions to grant European and Israeli Patent Applications. These patents, once approved will protect the cell-based product and a method of manufacturing stem and progenitor cell population with enhanced activity by short incjubation with an apoptotic ligand that is being developed by APOP.

In a statement, Dr. Shai Yarkoni, CEO at APOP, had the following to offer:

Continued recognition from global jurisdictions validates the breadth of Cellect’s technology. These latest acknowledgments are significant as they cover the ability to activate stem cells, therefore improving stem cell products and manufacturing processes. Our collaboration efforts with companies in Germany, Korea and Israel have each reported similar data using our process in various tissue sources (including fat derived cells). These added protections continue to create barriers to entry and allows us to advance our business development strategies to monetize our innovation.

We believe the combination of strong IP protection and validated business collaborations support our business model and will enable us to attract external resources to strengthen and expand our opportunities.

Why This News Is So Important

At the end of the day, it’s always important for companies to protect their inventions. After all, without IP, competition could simply copy the company’s work. So, any time we see enhanced IP protection, as we’re seeing from Cellect Biotechnology, it’s good news. However, the positive feeling from this release goes far further than just providing another piece of IP.

The company’s invention has been proven to significantly improve both proliferation and functional capabilities of hematopoietic and mesenchymal stem cells originating from bone marrow, peripheral blood, umbilical cord and adipose tissue. This gives the company a competitive advantage should the development of this option continue to be so positive.

As far as the patents go, once approved, they will cover an ex vivo method for obtaining an improved population of stem and progenitor cells with enhanced engraftment characteristics by activation of TNF family receptors.

All told, APOP currently holds 65 patent applications with 33 of these applications being issued or allowed.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.